InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-41.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Drachman Jonathan G, Chairman & CEO. Director active across 3 companies, notably Neoleukin Therapeutics, Inc.. Cumulatively, 5 filings have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €833k. Activity tracked since 3 June 2021. The latest transaction was disclosed on 8 March 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Drachman Jonathan G
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
415 shares0Common StockSEC:0000950170-24-029434:0
5,000 shares0Common StockSEC:0001209191-23-056795:0
200,000 shares@ €0.741250.0% of flowCommon StockSEC:0000899243-21-044150:0
Canonical exit: 8 Feb 2022 (T+90)
100,000 shares@ US$6.11162.5% of flowCommon StockSEC:0001209191-21-053544:0
Canonical exit: 22 Nov 2021 (T+90)
40,000 shares@ US$9.481837.5% of flowCommon StockSEC:0001209191-21-038690:0
Canonical exit: 1 Sept 2021 (T+90)
5 of 5 declarations
About Drachman Jonathan G
Jonathan G. Drachman is President and CEO of Neoleukin Therapeutics, Inc. and Calithera Biosciences, Inc. He leads these companies with a strategic vision, overseeing all operations and ensuring performance objectives are met. His leadership is crucial for the development of these biopharmaceutical firms.
